Amy E. Gillgrass, Ali A. Ashkar, Kenneth L. Rosenthal, and Charu Kaushic*
|
|
- Harry Farmer
- 5 years ago
- Views:
Transcription
1 JOURNAL OF VIROLOGY, Sept. 2003, p Vol. 77, No X/03/$ DOI: /JVI Copyright 2003, American Society for Microbiology. All Rights Reserved. Prolonged Exposure to Progesterone Prevents Induction of Protective Mucosal Responses following Intravaginal Immunization with Attenuated Herpes Simplex Virus Type 2 Amy E. Gillgrass, Ali A. Ashkar, Kenneth L. Rosenthal, and Charu Kaushic* Center of Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University Health Sciences Center, Hamilton, Ontario, Canada Received 23 April 2003/Accepted 23 June 2003 Depo-Provera (Depo) is a long-acting progestational formulation that is a popular form of contraception for women. In animal models of sexually transmitted diseases, it is used to facilitate infection. Here we report that treatment with Depo, in a mouse model of genital herpes simplex virus type 2 (HSV-2), altered immune responses depending on the length of time that animals were exposed to Depo prior to immunization. Mice immunized intravaginally (i.vag.) with an attenuated strain (TK ) of HSV-2 following longer (15 days) exposure to Depo (Depo 15 group) failed to show protection when challenged with wild-type HSV-2. In contrast, mice that were immunized shortly after Depo treatment (5 days; Depo 5 group) were fully protected and showed no genital pathology after HSV-2 challenge. High viral titers were detected in the vaginal washes of the Depo 15 group up to 6 days postchallenge. In contrast, no viral shedding was observed beyond day 3 postchallenge in the Depo 5 group. Following i.vag. TK immunization, high levels of gamma interferon (IFN- ) were detected locally in vaginal washes of the Depo 5 group but not the Depo 15 group. After HSV-2 challenge, an early peak of IFN- in the Depo 5 group coincided with clearance of the virus. In Depo 15 animals IFN- was present throughout the 6 days postinfection. HSV-2-specific T-cell cytokine responses measured in the lymph node cells of Depo 5 TK -immunized mice indicated a significantly higher Th1 response than that of Depo 15 TK -immunized mice. The protection after HSV-2 challenge in the Depo 5 group correlated with increased local HSV-2 glycoprotein B (gb)-specific immunoglobulin G (IgG) and IgA responses seen in the vaginal secretions. The Depo 15 group had poor gb-specific antibody responses in the genital tract after HSV-2 challenge. These results indicate that longer exposure to Depo leads to poor innate and adaptive immune responses to HSV-2 that fail to protect mice from subsequent genital challenges. Downloaded from Sexually transmitted diseases (STDs), including human immunodeficiency virus (HIV) infection-aids, are a leading cause of morbidity and a huge economic burden on health systems in both developing and developed countries. Herpes simplex virus type 2 (HSV-2) is the causative agent of one of the most commonly transmitted viral STDs (1). Currently in North America, one out of every four adults is estimated to be seropositive for HSV-2 (6). Attempts at developing an effective vaccine have been unproductive over the last 4 decades. A successful prophylactic vaccine for sexually transmitted infections will have to induce a good local immune response in the genital tract where infection is initiated (13). In order to achieve this, factors that affect mucosal immune responses in the reproductive tract need to be taken into consideration. That these factors are important is demonstrated by a recent clinical trial of a glycoprotein D-based HSV-2 vaccine that reported limited success only in women and not in men (25). Gender-based factors that may affect the immune system may therefore play a critical role in the success of STD vaccines. Various studies have shown that sex hormones have a profound effect on susceptibility to STDs and immune responses in females (8, 12, 15, 24, 27, 28). Hormonal contraception, such * Corresponding author. Mailing address: Department of Pathology and Molecular Medicine, HSC, 4H30F, McMaster University, 1200 Main St. West, Hamilton, Ontario, Canada L8P 3Z5. Phone: (905) , ext Fax: (905) kaushic@mcmaster.ca. as oral contraceptives and progesterone-based methods (Depo- Provera [Depo]), has been shown in various studies to be a biologic factor linked to HIV type 1 acquisition (14). In our own studies we have seen that rats that are normally resistant to genital infection by Chlamydia trachomatis are rendered susceptible following progesterone treatment (11). Other studies have shown that simian immunodeficiency virus (SIV) genital infection and disease course are enhanced by progesterone implants (15). Depo is a progesterone-based popular contraceptive. It is a long-acting (Depo) formulation of medroxyprogesterone acetate that was approved by the Food and Drug Administration for contraceptive use in women in It is effective for periods of 3 months, and patients receive injections at 3-month intervals (7). This form of contraception is currently being promoted as an attractive contraception option for adolescents due to its high efficacy and ease of compliance (26). In mouse studies of HSV-2, Depo is commonly used to facilitate infection. Many studies have utilized Depo-treated mice to examine the infection kinetics and immune responses to HSV-2 (9, 16, 17, 21). In all of these studies mice are administered subcutaneous Depo and shortly after (within a week) immunized or infected. We recently reported that Depo changes the susceptibility of treated mice to HSV-2 infection. Depo-treated mice were found to be 100-fold more susceptible than untreated mice in diestrus (10). Additionally, we reported a significant lowering of antibody responses to HSV-2 in immunized mice following Depo treatment. Interestingly, in on February 1, 2019 by guest 9845
2 9846 GILLGRASS ET AL. J. VIROL. these studies when mice were exposed to Depo for a longer time (2 weeks) prior to immunization with TK HSV-2, they failed to show any protection against subsequent challenge (10). Other studies using immunization protocols where mice were immunized 3 to 5 days after Depo treatment showed complete protection (16, 20, 21). The present study was undertaken to determine if indeed prolonged exposure to Depo prior to immunization results in failure to protect mice from subsequent challenge. Mice that were Depo treated 2 weeks prior to immunization were compared with mice that were exposed to Depo for 5 days before immunization. The effect of length of exposure to Depo on immune responses to HSV-2 was examined as well as its consequent effect on protection following challenge. Following immunization and challenge, viral shedding and pathology in the two groups of mice were compared. To examine the mechanism, the local immune responses in the genital tract and the draining lymph nodes (LN) were also measured. Finally mucosal antibody responses following challenge with wild-type HSV-2 were determined. MATERIALS AND METHODS Animals and hormone treatments. Inbred C57BL/6 mice, 8 to 10 weeks old, purchased from Charles River Canada (Constant, Quebec, Canada), were used in these studies. Mouse colonies were maintained on a 12-h-dark 12-h-light cycle. Mice were injected subcutaneously with 2 mg of Depo (Pharmacia-Upjohn, Don Mills, Ontario, Canada), based on previous studies (10). Inoculation of animals. Mice were anesthetized by injectable anesthetic (ketamine-xylazine, 0.75 and 0.25 ml, respectively) given intraperitoneally, placed on their backs, and inoculated intravaginally (i.vag.) with 10 l of wild-type HSV-2 strain 333 or the attenuated TK strain of HSV-2, each at a dose of 10 5 PFU per mouse. Mice were kept on their backs under the influence of anesthesia for 45 min to an hour to allow the inoculum to infect them. Vaginal smears and lavage collection. Vaginal lavage for reproductive cycle staging and plaque assays was collected by pipetting 2 30 l of phosphatebuffered saline (PBS) in and out of the vagina several times. For vaginal smears, the fluid was smeared on glass slides and examined by light microscopy to determine the stage of the estrous cycle as described before (30). The following classification was used for identifying the stage of the cycle: estrus, 90% cornified epithelial cells; diestrus, 75% polymorphonuclear cells; diestrus-estrus, 50% epithelial cells 50% polymorphonuclear cells. For plaque assays the vaginal washes were frozen at 70 C. Mice treated with Depo remained in diestrus for 5 to 6 weeks, as described before (10). Vaginal smears of both Depo 5 and Depo 15 mice were examined to confirm that they were all in diestrus stage prior to immunization with TK HSV-2 and challenge with wild-type HSV-2. Viral replication and pathology in the reproductive tract. Genital pathology following infection with HSV-2 was monitored daily and scored on a five-point scale: 0, no infection; 1, slight redness of external vagina; 2, swelling and redness of external vagina; 3, severe swelling and redness of both vagina and surrounding tissue and hair loss in genital area; 4, genital ulceration with severe redness, swelling, and hair loss of genital and surrounding tissue; and 5, severe genital ulceration extending to surrounding tissue. Animals were sacrificed after they reached stage 4. Vaginal washes or tissue homogenates were analyzed for viral titers by plaque assays. Vero cells were grown in alpha minimum essential medium (GIBCO Laboratories, Burlington, Canada) supplemented with 5% fetal calf serum (GIBCO), 1% penicillin streptomycin, and L-glutamine (GIBCO). For plaque assays, Vero cells were grown to confluence in 12-well plates. Samples were diluted (10 2 to 10 7 ) and added to monolayers. Infected monolayers were incubated at 37 C for 2 h for viral absorption. Infected monolayers were overlaid with alpha minimum essential medium supplemented with 0.05% human immune serum globulin (Canadian Blood Services). Infection was allowed to occur for 48 h at 37 C. Monolayers were then fixed and stained with crystal violet, and viral plaques were counted under a light microscope. PFU per milliliter was calculated by taking a plaque count for every sample and taking into account the dilution factors. ELISA for anti-hsv-2 gb IgG and IgA. HSV-2 glycoprotein B (gb)-specific antibody titers were determined by an enzyme-linked immunosorbent assay (ELISA) modified from a protocol described previously (8). Briefly Maxisorp 96 FIG. 1. Pathology of mice immunized with TK HSV-2 and challenged with wild-type HSV-2 strain 333. Both groups of mice (six per group) were given Depo (2 mg/mouse) subcutaneously and immunized i.vag. with 10 5 PFU of TK HSV-2. One group was immunized 15 days after Depo treatment (Depo 15 group) while the other was immunized 5 days after Depo treatment (Depo 5 group). Both groups were challenged i.vag. with 10 5 PFU of HSV-2 strain weeks later. Pathology was scored for all animals as explained in Materials and Methods. Data shown are representative of three independent experiments with comparable results. plates (Invitrogen, Burlington, Ontario, Canada) were coated overnight with 2.5 g of recombinant gb protein (Chiron Inc., Emeryville, Calif.)/ml in PBS at 4 C. Plates were blocked with 2% bovine serum albumin for 2 h at room temperature and loaded with 100 l of twofold serial dilutions of samples or controls. Incubation was carried out at 4 C overnight. Plates were washed and reacted for 1 h with one of the following biotinylated antibodies: goat anti-mouse IgG or goat anti-mouse IgA at a 1:1,000 dilution (PharMingen, Mississauga, Ontario, Canada). Plates were developed with extravidin-peroxidase (1:2,000 dilution) and 3,3,5,5 -tetramethylbenzidine. Endpoint titers were determined and expressed as geometric mean titers standard errors (SEs) of the means. Background values were obtained by using vaginal lavage samples from nonimmunized mice. Two times the mean background optical density value was taken as the cutoff for determining positive values. LN cell preparation and culture. Iliac LN that drain the genital tract were dissected, and single-cell suspensions were prepared by teasing the LN. Debris was allowed to settle for 2 min, and supernatant containing single cells was recovered and spun down at 500 g for 7 to 10 min. Cells were washed with RPMI 1640 medium containing 5% bovine serum albumin and plated at the density of cells/well in a 96-well plate. Cells were tested for HSV-2- specific proliferation by addition of gb (10 g/ml) (Chiron Inc.) in triplicate cultures. Total T-cell proliferation was measured by adding cells to plates coated with anti-cd3 antibody (20 g/well; purified from clone 2C11, generously provided by D. P. Snider, McMaster University). Cultures were incubated for 48 h, and supernatants were collected and frozen for further testing. Proliferative responses were measured by uptake of 1 Ci of [ 3 H]thymidine per well for the
3 VOL. 77, 2003 PROGESTERONE EXPOSURE INHIBITS MUCOSAL IMMUNITY 9847 FIG. 2. Viral titers in the vaginal washes of mice immunized with TK HSV-2 after 15 or 5 days of Depo treatment (A) and challenged with HSV-2 i.vag. 3 weeks later (B). Twelve mice per group were immunized with 10 5 PFU of TK HSV-2. Vaginal washes were collected daily in PBS, and viral plaque assays were performed to enumerate viral shedding. Plaques were counted, and viral titers were expressed as PFU per milliliter. Each symbol represents a single animal. Data shown are representative of at least three independent experiments with similar results. The dotted lines show the lower detection limit of the viral plaque assay. last 18 h of a 3-day culture. Results are reported as mean counts per minute SEs of the means of triplicate cultures. Cytokine ELISAs. Cytokine levels were measured in LN supernatants by using commercial ELISA kits from R&D Systems (Minneapolis, Minn.) according to the protocol recommended in the kits. Fifty-microliter aliquots of collected supernatants were run in duplicate. Absorbance was read at 450 nm. A standard curve was used to calculate the picograms-per-milliliter concentration in each sample. The ratios of gamma interferon (IFN- ) to interleukin 10 (IL-10) and of IFN- to IL-4 were calculated for each animal, and mean SE was calculated for each experimental group. Statistical analysis. Each experiment was repeated at least two times with 6 to 12 animals in each group. Data were analyzed by the unpaired two-tailed t test using SPSS for Windows software. Significance was defined as a P value of RESULTS Immunization with TK HSV-2 15 days after exposure to Depo leads to decreased protection following HSV-2 challenge. Two groups of mice were treated with a single injection of Depo and immunized with 10 5 PFU of TK HSV-2 i.vag. One group was vaccinated 15 days after Depo treatment (Depo 15 group), and the other group was vaccinated 5 days after administration of Depo (Depo 5 group). Following Depo treatment, all the mice were in diestrus between 5 and 6 weeks as reported before (10). Vaginal smears were examined prior to challenge to confirm that mice in both Depo 15 and Depo 5 groups were in diestrus. There was no difference in the pathology of animals in either group following immunization (data not shown). Animals in both groups showed signs of mild local infection with some redness and inflammation in the genital area for 3 to 4 days before resolving the infection. Three weeks after immunization both groups were challenged i.vag. with 10 5 PFU of wild-type HSV-2 strain 333. Data from one of three separate experiments are shown in Fig. 1. Gross daily examination following the challenge showed that animals in the Depo 5 group had no or minimal signs of vaginal pathology. In contrast, four out of six animals in the Depo 15 group started showing vaginal pathology within 72 h of HSV-2 challenge and by day 6 had severe pathology with scores of 3 to 4 on the scale and had to be euthanized. Similar results were seen in two other experiments, where 60 to 80% of Depo 15 animals succumbed to infection. Viral shedding patterns following immunization with TK HSV-2 and subsequent challenge with HSV-2. To examine if the differences in the protection seen in the two groups of mice were correlated with the ability of TK virus to infect the genital tract, we examined viral titers after immunization as well as following challenge with wild-type HSV-2. Following TK HSV-2 immunization viral titers in vaginal secretions were similar in both the Depo 15 and Depo 5 groups (Fig. 2A). After HSV-2 challenge, viral titers measured in vaginal washes
4 9848 GILLGRASS ET AL. J. VIROL. Downloaded from FIG. 3. IFN- concentrations in vaginal washes of mice after immunization with TK HSV-2 and after HSV-2 strain 333 challenge. Mice were immunized (six in each group) with 10 5 PFU of TK HSV-2 15 or 5 days after Depo treatment and challenged i.vag. with 10 5 PFU of HSV-2 3 weeks later. Vaginal washes were collected daily after immunization and postchallenge. Vaginal washes from all six animals were pooled due to the small sample volume available from each mouse, and IFN- levels were measured by ELISA. The data are representative of those obtained from two independent experiments with comparable results. (A) Mice immunized with TK HSV-2 15 days after Depo treatment. (B) Mice immunized with TK HSV-2 5 days after Depo treatment. (C) Depo 15 mice postchallenge. (D) Depo 5 mice postchallenge. showed good correlation with pathology data (Fig. 2B). All the animals in the Depo 5 group resolved the infection within 3 days, and subsequently no viral titers were detected in their vaginal washes. In contrast, four out of six animals in the Depo 15 group had high viral titers on all six days on which the shedding was measured. These animals were the same ones that exhibited severe pathology (Fig. 1). IFN- levels in vaginal washes postimmunization and postchallenge. The results from the previous experiments made it clear that 5-day Depo treatment allowed protection of mice from subsequent HSV-2 challenge but 15-day Depo treatment did not. Previous studies have shown that IFN- secreted into vaginal secretions is a good indicator of local antiviral responses (18). To examine if there were differences in local IFN- production in the infected animals, we examined IFN- levels in vaginal secretions. Following immunization with TK HSV-2, the Depo 5 group showed an early peak of IFN- secreted into the vaginal secretions on day 2 postimmunization, as has been reported in other studies (Fig. 3B). This early peak of IFN- was not present in the Depo 15 group. Very low levels of IFN- were detected in the vaginal washes of this group following immunization (Fig. 3A). Following HSV-2 challenge, the Depo 5 animals showed an early peak of IFN- secretion starting on day 1 postchallenge. The levels decreased to below detectability by day 4, coinciding with the virus clearance pattern (Fig. 3D). On the other hand, in Depo 15 animals, IFN- response peaked at day 2 postchallenge and showed the typical biphasic pattern seen in other studies (18), following primary exposure to virus, with high levels of IFN- still present on day 6 postchallenge (Fig. 3C). T-cell responses in the draining LN of TK HSV-2-immunized mice. Since we observed a decreased local IFN- response in vaginal secretions in the Depo 15 group following TK HSV-2 immunization, we examined, 5 days after immunization in the two groups of mice, T-cell immune responses in the local LN draining the genital tract. The time kinetics of T-cell responses in the draining LN was determined prior to these experiments, and day 5 postimmunization was found to on February 1, 2019 by guest
5 VOL. 77, 2003 PROGESTERONE EXPOSURE INHIBITS MUCOSAL IMMUNITY 9849 FIG. 4. LN proliferation and cytokine responses in Depo-treated mice immunized with TK HSV-2. Mice were immunized (six in each group) with 10 5 PFU of TK HSV-2 15 or 5 days after Depo treatment. Iliac LN were extracted 5 days postimmunization, and cells were cultured for 48 h as described in Materials and Methods. (A) LN cell proliferation was measured in response to anti-cd3 antibody (CD3) and HSV-2 gb. Control cultures received medium alone. Results are shown as means SEs. (B to D) Supernatants were collected after 48 h of culture with gb protein and analyzed by ELISA for IFN-, IL-4, and IL-10, respectively. Th1/Th2 ratios were calculated for each animal, and means SEs are shown for each group. (E) IFN- /IL-4 ratio. (F) IFN- /IL-10 ratio. Data shown are representative of two independent experiments with similar results. be the optimal time to measure HSV-2-specific LN T-cell responses (data not shown). To examine total T-cell responses following immunization, LN T cells were activated in vitro by anti-cd3 antibody. HSV-2-specific responses were measured by in vitro stimulation with gb, a highly immunogenic HSV-2 envelope glycoprotein. Following TK immunization, LN cells from Depo 15 and Depo 5 groups had no significant differences in proliferative responses to in vitro gb challenge or stimulation by anti-cd3 antibody (Fig. 4A). However, when cytokine profiles were examined in culture supernatants from in vitro gb-challenged LN cells, Depo 5 cultures had about threefold-higher levels of IFN- than did Depo 15 LN cultures (Fig. 4B). IL-4 levels were lower and IL-10 levels were higher in the Depo 5 group than in the Depo 15 group, although these levels did not show statistical significance (Fig. 4C and D). However, when Th1/Th2 ratios were calculated, Depo 5 LN cultures had more-than-fourfold-higher IFN- /IL-4 ratios (P 0.01) (Fig. 4E). Similarly, a threefold increase in IFN- / IL-10 ratio was seen in supernatants of the Depo 5 group compared to the Depo 15 group (Fig. 4F). T-cell responses were also examined 5 days following HSV-2 challenge (data not shown). In agreement with the observations made on viral shedding and IFN- response in the vaginal secretions, by day 5 postchallenge, T-cell responses in Depo 5 animals were past their peak and all the cytokine levels were comparable to those for uninfected mice. On the other hand, Depo 15 LN showed significantly higher levels of IFN- and Th1/Th2 ratios were significantly high, indicating a primary response to HSV-2. HSV-2-specific IgG and IgA levels in vaginal washes. Previous studies have demonstrated that protection against genital HSV-2 infection correlates with local antibody levels in the vaginal secretions (8, 20). Since differences were observed in protection against HSV-2 challenge between Depo 15 and Depo 5 mice, local antibodies to gb in vaginal secretions were measured to determine if Depo treatment had an effect on secondary antibody responses to HSV-2. Representative data from one of the three experiments are shown in Fig. 5. All six mice in the Depo 15 group had poor gb-specific IgA responses, while three out of six mice in the Depo 5 group showed significant gb-specific IgA levels in the vaginal washes. Differences in gb-specific IgG were even more dramatic. All six mice in the Depo 5 group had gb-specific IgG responses, and four out of six had endpoint titers between 1,000 and 5,000. One out of six Depo 15 mice had a detectable level of gb-specific IgG in its vaginal secretions. DISCUSSION The results from this study clearly show that length of exposure to Depo had a significant influence on immune responses following immunization with an attenuated strain of HSV-2. The changes in immune responses resulted in mice being protected or not from subsequent challenge with wildtype virus. Previous studies have shown that immunization with TK HSV-2 3 to 5 days following Depo treatment leads to complete protection against subsequent challenge (16, 21). In our study we found similar results, where shorter exposure to
6 9850 GILLGRASS ET AL. J. VIROL. FIG. 5. HSV-2-specific antibody titers in vaginal washes of Depo 15 and Depo 5 animals following HSV-2 challenge. Mice were immunized (six in each group) with 10 5 PFU of TK HSV-2 15 or 5 days after Depo treatment and challenged i.vag. with 10 5 PFU of HSV-2 3 weeks later. Vaginal washes were collected daily for 5 days postchallenge and pooled for each animal. gb-specific IgA and IgG antibodies were measured by ELISA, and endpoint titers were determined as described in Materials and Methods. The dotted line shows the lower limit of detection of the ELISA. The value is too low to be seen in panel B. Data shown are representative of two independent experiments with comparable results. Depo (5 days) induced immune responses adequate to protect against subsequent i.vag. challenge. In contrast, longer exposure (2 weeks) to Depo inhibited induction of immune responses and failed to provide protection against subsequent genital challenge with wild-type HSV-2. Following immunization, there was a lack of induction of IFN- in vaginal secretions of Depo 15 mice, indicating that local innate responses were compromised. There was also a lowered Th1 response in the local draining LN of Depo 15 mice. Following challenge with wild-type HSV-2, inadequate protection in the Depo 15 group correlated with the absence of local antibody responses in the genital tract compared to the Depo 5 group. While previous clinical and experimental studies have clearly shown that progesterone increases susceptibility to STDs, the present study starts to delineate the effects on immune responses. The most intriguing observation was the suppressive effect of progesterone on innate immune responses following immunization with TK HSV-2. Previous studies have shown that in response to primary vaginal infection with HSV-2 there is a biphasic secretion of IFN- which plays an important role in clearance of virus (18). The early peak of IFN- seen in vaginal secretions is part of the innate response produced primarily by NK and NKT cells in response to the viral infection (18). Studies in other infection models have shown that IFN- produced by NK cells plays an important role in skewing the developing immune response to Th1 type (23). Local IFN- may also play an important role in activating the antigen-presenting cells and upregulating major histocompatibility complex class II on antigen-presenting cells, to enhance presentation of viral antigens (4). This early IFN- response is absent in animals with prolonged exposure to Depo, indicating a possible deficiency in the initiation of an innate response to HSV-2 immunization. In other studies from our group, mice that genetically lack the ability to mount this initial innate response (IFN- / and Rag-2 / / c / mice) also showed a significant increase in susceptibility to HSV-2 genital infection (2). The progesterone effect was also evident on adaptive immune responses to HSV-2 immunization. The Th1/Th2 ratios were significantly lowered in Depo 15 mice following immunization, as were the local antiviral IgA and IgG antibody levels following challenge. One possibility is that the lack of the initial innate response affected subsequent induction of protective adaptive immune responses. The absence of IFN- in the early innate response could alter the Th1 response to more of a Th2 response and consequently affect mucosal antibody responses. On the other hand, both the innate and adaptive responses may be independently inhibited by Depo. It was recently reported that, when Depo was administered in previously immunized mice, the IgG and IgA antibody levels were lowered dramatically in the vaginal secretions, indicating that Depo may directly inhibit local antibody levels (10). The cellular mechanism by which longer exposure to progesterone downregulates the protective immune response is not clear. Our data suggest that the effect requires more than 5 days of exposure to Depo. Results from other studies indicate that progesterone can exert a suppressive effect on neutrophils (19) and NK cell function (5). It is therefore possible that prolonged exposure to Depo may affect the ability of these cells to secrete appropriate chemokines and cytokines to initiate an antiviral innate immune response. Clinical studies in tumor research have also shown that continuous or intermittent scheduled administration of medroxyprogesterone acetate can lead to cell cycle arrest of human hematopoietic progenitors (22). If this mechanism is active in this HSV-2 model, then under the influence of long-term exposure to Depo progenitor immune cells may not be able to proliferate, resulting in a reduced antiviral response. We are currently investigating this possibility. The finding that progesterone enhances susceptibility to sexually transmitted viruses has been demonstrated by a number of other studies (12, 14, 15). In the rhesus macaque model of SIV it has been shown that progesterone implants enhance SIV vaginal transmission and virus load (15). The increase in transmission in this and other studies has been attributed to the atrophy of vaginal epithelium under the influence of progesterone. The thin epithelium may allow the virus to easily penetrate the epithelial layer and/or establish infection in sus-
7 VOL. 77, 2003 PROGESTERONE EXPOSURE INHIBITS MUCOSAL IMMUNITY 9851 ceptible target cells under the epithelium. While the present study was done in mice, the results from this study may have important implications for women using Depo as a method of contraception. In addition to thinning the genital epithelium, if continuous use of Depo also affects immune responses in the genital tract of women, then it may further increase the risk of sexually transmitted infections, including HIV. This is especially important in adolescent girls who represent the group at highest risk of contracting STDs (3). Studies need to be done to further examine if women who are on Depo or other hormonal therapies have altered susceptibility to STDs and/or immune responses to vaccines. If so, additional precautions such as barrier methods of contraception are important for women who are currently using hormonal contraceptives and therapies, to protect themselves against increased risk of transmission. The ultimate goal for a successful STD vaccine would be to induce sterile immunity in the genital tract. Previous studies have shown clearly that, in both animal models and women, reproductive tract immune responses are regulated by the sex hormones estradiol and progesterone (29). It was previously shown that estradiol and progesterone regulate susceptibility and immune responses in a rat model of C. trachomatis (12) and a mouse model of HSV-2 (10). The present study extends these findings by showing that hormonal treatments such as Depo may also affect the ability of the immune system to fight sexually transmitted viral infections. These studies emphasize the need to consider the hormonal status of women in order to develop effective STD vaccine strategies. It also has important implications for women who are currently on hormonal therapies. ACKNOWLEDGMENTS This work was supported by research grants from the Canadian Institutes of Health Research (to C.K. and K.L.R.), the Ontario HIV Treatment Network (C.K.), and the Bickell Foundation (C.K.). C.K. is an Ontario HIV Treatment Network Scholar. We acknowledge the technical help of Jen Newton and Amy Patrick. We also thank Denis Snider for critical reading of the manuscript. REFERENCES 1. Aral, S. O., and K. K. Holmes Social and behavioral determinants of the epidemiology of STDs: industrialized and developing countries, p In K. K. Holmes, P. F. Sparling, P. A. Mardh, S. M. Lemon, W. E. Stamm, P. Piot, and J. N. Wasserheit (ed.), Sexually transmitted diseases, 3rd ed. McGraw-Hill, New York, N.Y. 2. Ashkar, A. A., and K. L. Rosenthal Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J. Virol. 77: Berman, S. M., and K. Hein Adolescents and STDs, p In K. K. Holmes, P. F. Sparling, P. A. Mardh, S. M. Lemon, W. E. Stamm, P. Piot, and J. N. Wasserheit (ed.), Sexually transmitted diseases, 3rd ed. McGraw-Hill, New York, N.Y. 4. Bland, P MHC class II expression by gut epithelium. Immunol. Today 9: Brunelli, R., D. Frasca, G. Perrone, C. Pioli, A. Fattorossi, L. Zichella, and G. Dorai Hormone replacement therapy affects various immune cell subsets and natural cytotoxicity. Gynecol. Obstet. Investig. 41: Corey, L., and A. Wald Genital herpes, p In K. K. Holmes, P. F. Sparling, P. A. Mardh, S. M. Lemon, W. E. Stamm, P. Piot, and J. N. Wasserheit (ed.), Sexually transmitted diseases, 3rd ed. McGraw-Hill, New York, N.Y. 7. FDA Medical Bulletin month contraceptive injection approved. FDA Med. Bull. 23: Gallichan, W. S., and K. L. Rosenthal Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract. Virology 224: Gallichan, W. S., and K. L. Rosenthal Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med. 184: Kaushic, C., A. A. Ashkar, L. A. Reid, and K. L. Rosenthal Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J. Virol. 77: Kaushic, C., A. D. Murdin, B. J. Underdown, and C. R. Wira Chlamydia trachomatis infection in the female reproductive tract of the rat: influence of progesterone on infectivity and immune response. Infect. Immun. 66: Kaushic, C., F. Zhou, A. D. Murdin, and C. R. Wira Effect of estradiol and progesterone on susceptibility and immune responses to Chlamydia trachomatis infection in the female reproductive tract. Infect. Immun. 68: Lehner, T., L. Bergmeier, Y. Wang, L. Tao, and E. Mitchell A rational basis for mucosal vaccination against HIV infection. Immunol. Rev. 170: Martin, H. L., Jr., P. M. Nyange, B. A. Richardson, L. Lavreys, K. Mandaliya, D. J. Jackson, J. O. Ndinya-Achola, and J. Kreiss Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J. Infect. Dis. 178: Marx, P. A., A. I. Spira, A. Gettie, et al Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2: McDermott, M. R., J. R. Smiley, P. Leslie, J. Brais, H. E. Rudzroga, and J. Bienenstock Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J. Virol. 51: Milligan, G. N., and D. I. Bernstein Analysis of herpes specific T-cells in the murine female genital tract following genital infection with herpes virus type 2. Virology 212: Milligan, G. N., and D. I. Bernstein Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229: Nohmi, T., S. Abe, K. Dobashi, S. Tansho, and H. Yamaguchi Suppression of anti-candida activity of murine neutrophils by progesterone in vitro: a possible mechanism in pregnant women s vulnerability to vaginal candidiasis. Microbiol. Immunol. 39: Parr, E. L., and M. B. Parr Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology 98: Parr, M. B., L. Kepple, M. R. McDermott, M. D. Drew, J. J. Bozzola, and E. L. Parr A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab. Investig. 70: Quesada, A. R., J. M. Jimeno, G. Marquez, and M. Aracil Cell cycle arrest of human hematopoietic progenitors induced by medroxyprogesterone acetate. Exp. Hematol. 21: Scharton, T. M., and P. Scott Natural killer cells are a source of interferon gamma that drives differentiation of CD4 T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178: Smith, S. M., G. B. Baskin, and P. A. Marx Estrogen protects against vaginal transmission of simian immunodeficiency virus. J. Infect. Dis. 182: Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. L. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Sloui, M. Denis, P. Vandepapeliere, and G. Dubin Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347: Sucato, G., and M. A. Gold New options in contraception for adolescents. Curr. Women s Health Rep. 1: Teepe, A. G., L. B. Allen, R. J. Wordinger, and E. F. Harris Effect of the estrous cycle on susceptibility of female mice to intravaginal inoculation of herpes simplex virus type 2 (HSV-2). Antivir. Res. 14: Wira, C. R., and C. Kaushic Mucosal immunity in the female reproductive tract: effect of sex hormones on immune recognition and responses, p In H. Kiyono, P. L. Ogra, and J. R. McGhee (ed.), Mucosal vaccines: new trends in immunization. Academic Press, New York, N.Y. 29. Wira, C. R., C. Kaushic, and J. Richardson Role of sex hormones and cytokines in regulating mucosal immune system in the female reproductive tract, p In P. L. Ogra, J. Mestecky, M. Lamm, W. Strober, J. Bienenstock, and J. McGhee (ed.), Mucosal immunology, 2nd ed. Academic Press, New York, N.Y. 30. Wira, C. R., and R. M. Rossoll Antigen presenting cells in the female reproductive tract: influence of estrous cycle on antigen presentation by uterine epithelial and stromal cells. Endocrinology 136:
Amy E. Gillgrass, Vera A. Tang, Kate M. Towarnicki, Kenneth L. Rosenthal and Charu Kaushic /JVI
Protection against Genital Herpes Infection in Mice Immunized under Different Hormonal Conditions Correlates with Induction of Vagina-Associated Lymphoid Tissue Amy E. Gillgrass, Vera A. Tang, Kate M.
More informationEstradiol Regulates Susceptibility following Primary Exposure to Genital Herpes Simplex Virus Type 2, while Progesterone Induces Inflammation
JOURNAL OF VIROLOGY, Mar. 2005, p. 3107 3116 Vol. 79, No. 5 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.5.3107 3116.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Estradiol Regulates
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationHormonal Contraception and HIV
Hormonal Contraception and HIV A ROUNDTABLE AT THE INTEREST WORKSHOP, LUSAKA, 2014 Professor Helen Rees, Wits RHI, Johannesburg, SA Dr Mike Mbizvo, Zimbabwe Dr Chelsea Polis, USAID, Washington Dr Nelly
More informationChlamydia trachomatis Infection in the Female Reproductive Tract of the Rat: Influence of Progesterone on Infectivity and Immune Response
INFECTION AND IMMUNITY, Mar. 1998, p. 893 898 Vol. 66, No. 3 0019-9567/98/$04.00 0 Copyright 1998, American Society for Microbiology Chlamydia trachomatis Infection in the Female Reproductive Tract of
More informationEARL L. PARR* AND MARGARET B. PARR Department of Anatomy, School of Medicine, Southern Illinois University, Carbondale, Illinois
JOURNAL OF VIROLOGY, June 1998, p. 5137 5145 Vol. 72, No. 6 0022-538X/98/$04.00 0 Copyright 1998, American Society for Microbiology Immunoglobulin G, Plasma Cells, and Lymphocytes in the Murine Vagina
More informationEVALUATION OF THE EFFECTIVENESS OF A 7% ACCELERATED HYDROGEN PEROXIDE-BASED FORMULATION AGAINST CANINE PARVOVIRUS
Final report submitted to Virox Technologies, Inc. EVALUATION OF THE EFFECTIVENESS OF A 7% ACCELERATED HYDROGEN PEROXIDE-BASED FORMULATION AGAINST CANINE PARVOVIRUS Syed A. Sattar, M.Sc., Dip. Bact., M.S.,
More informationChapter 24 The Immune System
Chapter 24 The Immune System The Immune System Layered defense system The skin and chemical barriers The innate and adaptive immune systems Immunity The body s ability to recognize and destroy specific
More informationThe Ticking CLOCK of HSV-2 Pathology Rebecca J. Bayliss 1 and Vincent Piguet 1,2,3
The Ticking CLOCK of HSV-2 Pathology Rebecca J. Bayliss 1 and Vincent Piguet 1,2,3 1 Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK; 2 Division of Dermatology, Women
More informationRNA-Dependent Protein Kinase Is Required for Alpha-1 Interferon Transgene-Induced Resistance to Genital Herpes Simplex Virus Type 2
JOURNAL OF VIROLOGY, July 2005, p. 9341 9345 Vol. 79, No. 14 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.14.9341 9345.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. RNA-Dependent
More informationSupporting Information
Supporting Information Aldridge et al. 10.1073/pnas.0900655106 Fig. S1. Flow diagram of sublethal (a) and lethal (b) influenza virus infections. (a) Infection of lung epithelial cells by influenza virus
More informationImmunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008
Immunity to Viruses Patricia Fitzgerald-Bocarsly September 25, 2008 The Immune System Deals with a Huge Range of Pathogens Roitt, 2003 Immune Responses to Viruses Viruses are dependent on the host cell
More informationNature Immunology: doi: /ni Supplementary Figure 1. Production of cytokines and chemokines after vaginal HSV-2 infection.
Supplementary Figure 1 Production of cytokines and chemokines after vaginal HSV-2 infection. C57BL/6 mice were (a) treated intravaginally with 20 µl of PBS or infected with 6.7x10 4 pfu of HSV-2 in the
More informationSupplementary Figures
Inhibition of Pulmonary Anti Bacterial Defense by IFN γ During Recovery from Influenza Infection By Keer Sun and Dennis W. Metzger Supplementary Figures d a Ly6G Percentage survival f 1 75 5 1 25 1 5 1
More informationMedicaid Family Planning Waiver Services CPT Codes and ICD-10 Diagnosis Codes
CPT Code Description of Covered Codes Evaluation and Management 99384FP 99385FP Family planning new visit 99386FP 99394FP 99395FP Family planning established visit 99396FP 99401FP HIV counseling (pre-test)
More informationCan HPV, cervical neoplasia or. HIV transmission?
Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV Jennifer S. Smith Department of Epidemiology pd University of North Carolina Can HPV, cervical
More informationUnderstanding basic immunology. Dr Mary Nowlan
Understanding basic immunology Dr Mary Nowlan 1 Immunology Immunology the study of how the body fights disease and infection Immunity State of being able to resist a particular infection or toxin 2 Overview
More informationClass-Specific Antibody Response in Acyclovir- Treated and Adenine Arabinoside-Treated Patients with Primary Genital Herpes Simplex Virus Infection
Microbiol. Immunol., 39(10), 795-799, 1995 Class-Specific Antibody Response in Acyclovir- Treated and Adenine Arabinoside-Treated Patients with Primary Genital Herpes Simplex Virus Infection Takashi Kawana*,1,
More informationThe Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep
The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep invaders out of the body (pp. 772 773; Fig. 21.1; Table
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More information3. Lymphocyte proliferation (fig. 15.4): Clones of responder cells and memory cells are derived from B cells and T cells.
Chapter 15 Adaptive, Specific Immunity and Immunization* *Lecture notes are to be used as a study guide only and do not represent the comprehensive information you will need to know for the exams. Specific
More informationDuring Murine Cytomegalovirus Infection
INFECTION AND IMMUNITY, Sept. 1980, p. 1050-1054 0019-9567/80/09-1050/05$02.00/0 Vol. 29, No. 3 Antivirus Antibody-Dependent Cell-Mediated Cytotoxicity During Murine Cytomegalovirus Infection JODY E. MANISCHEWITZ
More informationAntibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center
Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,
More informationFluid movement in capillaries. Not all fluid is reclaimed at the venous end of the capillaries; that is the job of the lymphatic system
Capillary exchange Fluid movement in capillaries Not all fluid is reclaimed at the venous end of the capillaries; that is the job of the lymphatic system Lymphatic vessels Lymphatic capillaries permeate
More informationWhat is the immune system? Types of Immunity. Pasteur and rabies vaccine. Historical Role of smallpox. Recognition Response
Recognition Response Effector memory What is the immune system? Types of Immunity Innate Adaptive Anergy: : no response Harmful response: Autoimmunity Historical Role of smallpox Pasteur and rabies vaccine
More informationAntivirals and Vaccines: What s old and new in HSV-2 treatment
Antivirals and Vaccines: What s old and new in HSV-2 treatment Christine Johnston, MD, MPH Last Updated: January 19, 2018 uwptc@uw.edu uwptc.org 206-685-9850 Importance of HSV: Why pursue a vaccine? Prevention
More informationINTRABULBAR INOCULATION OF JAPANESE ENCEPHALITIS VIRUS TO MICE
THE KURUME MEDICAL JOURNAL Vol. 15, No. 1, 1968 INTRABULBAR INOCULATION OF JAPANESE ENCEPHALITIS VIRUS TO MICE TOSHINORI TSUCHIYA Department of Microbiology, and Department of Ophthalmology, Kurume University
More informationImmunological Changes in the FRT During the Menstrual Cycle
Immunological Changes in the FRT During the Menstrual Cycle Charles R. Wira PhD Department of Physiology and Neurobiology Geisel School of Medicine at Dartmouth Lebanon, NH 03756 May 1, 2014 Anatomy and
More informationSupporting Information
Supporting Information Valkenburg et al. 10.1073/pnas.1403684111 SI Materials and Methods ELISA and Microneutralization. Sera were treated with Receptor Destroying Enzyme II (RDE II, Accurate) before ELISA
More informationRole of Interferon in the Propagation of MM Virus in L Cells
APPLIED MICROBIOLOGY, Oct. 1969, p. 584-588 Copyright ( 1969 American Society for Microbiology Vol. 18, No. 4 Printed in U S A. Role of Interferon in the Propagation of MM Virus in L Cells DAVID J. GIRON
More informationSupporting Online Material for
www.sciencemag.org/cgi/content/full/1175194/dc1 Supporting Online Material for A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection John S. Yi, Ming Du, Allan J. Zajac* *To whom
More informationThe Immune System. These are classified as the Innate and Adaptive Immune Responses. Innate Immunity
The Immune System Biological mechanisms that defend an organism must be 1. triggered by a stimulus upon injury or pathogen attack 2. able to counteract the injury or invasion 3. able to recognise foreign
More informationReceived 4 December 2001/Accepted 29 April 2002
JOURNAL OF VIROLOGY, Aug. 2002, p. 8433 8445 Vol. 76, No. 16 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.16.8433 8445.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. The Relationship
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationReceived 29 August 2002/Accepted 3 December 2002
JOURNAL OF VIROLOGY, Mar. 2003, p. 3099 3118 Vol. 77, No. 5 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.5.3099 3118.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Simian-Human
More informationB eyond individual benefits, the public health significance
24 ORIGINAL ARTICLE The potential epidemiological impact of a genital herpes vaccine for women G P Garnett, G Dubin, M Slaoui, T Darcis... See end of article for authors affiliations... Correspondence
More informationSecretory IgA against herpes simplex virus in cervical
Genitourin Med 1988;64:373-377 Secretory IgA against herpes simplex virus in cervical secretions ELISABETH PERSSON,* PETER ENEROTH,t STIG JEANSSONt From the *Department of Obstetrics and Gynaecology, Karolinska
More informationPERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES
71 PERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES Harold G. Jensen, Alan J. Parkinson, and L. Vernon Scott* Department of Microbiology & Immunology, University of Oklahoma
More informationSexually Transmi/ed Diseases
Sexually Transmi/ed Diseases Chapter Fourteen 2013 McGraw-Hill Higher Education. All rights reserved. Also known as sexually transmitted infections The Major STDs (STIs) HIV/AIDS Chlamydia Gonorrhea Human
More informationChapter 38- Immune System
Chapter 38- Immune System First Line of Defense: Barriers Nonspecific defenses, such as the skin and mucous membranes, are barriers to potential pathogens. In addition to being a physical barrier to pathogens,
More informationIdentification of Microbes Lecture: 12
Diagnostic Microbiology Identification of Microbes Lecture: 12 Electron Microscopy 106 virus particles per ml required for visualization, 50,000-60,000 magnification normally used. Viruses may be detected
More informationThe Case of the Spring Break Consequences
The Case of the Spring Break Consequences Hazel reluctantly opened her eyes when her alarm went off. Spring Break was over, and she was definitely NOT ready for the second half of the semester. However,
More informationCritical Role for Alpha/Beta and Gamma Interferons in Persistence of Lymphocytic Choriomeningitis Virus by Clonal Exhaustion of Cytotoxic T Cells
JOURNAL OF VIROLOGY, Sept. 2001, p. 8407 8423 Vol. 75, No. 18 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.18.8407 8423.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Critical
More informationQuantitative Assay of Paravaccinia Virus Based
APPrU MICROBIOLOGY, JUly 1972, p. 138-142 Copyright 1972 American Society for Microbiology Vol. 24, No. 1 Printed in U.S.A. Quantitative Assay of Paravaccinia Virus Based on Enumeration of Inclusion-Containing
More informationInnate Immunity. Bởi: OpenStaxCollege
Innate Immunity Bởi: OpenStaxCollege The vertebrate, including human, immune system is a complex multilayered system for defending against external and internal threats to the integrity of the body. The
More informationImmune Surveillance. Immune Surveillance. Immune Surveillance. Neutrophil granulocytes Macrophages. M-cells
he immune system is everywhere Some organs have developed strategies towards the immune system to keep it out or to put it under control Immune privileged organs: Brain Eye estis hyroid gland Humoral immunity
More informationThe Immune System. Protective system that fight disease in the body. Includes parts of the circulatory system and lymph system.
The Immune System Protective system that fight disease in the body. Includes parts of the circulatory system and lymph system. The immune system recognizes, attacks, destroys, and remembers each kind of
More informationHuman Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set
Human Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set Catalog Number : SEK11233 To achieve the best assay results, this manual must be read carefully before using this product
More informationCytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,
Cytokines http://highered.mcgraw-hill.com/sites/0072507470/student_view0/chapter22/animation the_immune_response.html Cytokines modulate the functional activities of individual cells and tissues both under
More informationThe immune response against Chlamydia suis genital tract infection partially protects against re-infection
UGhent Center for Strategic Prophylaxis and Vaccine Development The immune response against Chlamydia suis genital tract infection partially protects against re-infection E. De Clercq 1, B. Devriendt 2,
More informationBlocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model
JOURNAL OF VIROLOGY, Apr. 2009, p. 2803 2818 Vol. 83, No. 7 0022-538X/09/$08.00 0 doi:10.1128/jvi.02424-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Blocking Interhost Transmission
More informationAnimal Models to Understand Immunity
Animal Models to Understand Immunity Hussein El Saghire hesaghir@sckcen.be Innate Adaptive immunity Immunity MAPK and NF-kB TLR pathways receptors Fast Slow Non-specific Specific NOD-like receptors T-cell
More informationLooking at NY: Our rate of chlamydia is higher than the US as a whole; we rank 13th among all states.
1 In this presentation, we will discuss: What are the most common STDs in NYS What are the most common STDs Can I get gonorrhea from oral sex How do you know if you/or your partner has an STD? Does getting
More informationGenital Herpes in the STD Clinic
Genital Herpes in the STD Clinic Christine Johnston, MD, MPH Last Updated: 5/23/2016 uwptc@uw.edu uwptc.org 206-685-9850 Importance of HSV HSV is the leading cause of GUD - HSV is very common HSV-2: 16%
More informationImmunity. Acquired immunity differs from innate immunity in specificity & memory from 1 st exposure
Immunity (1) Non specific (innate) immunity (2) Specific (acquired) immunity Characters: (1) Non specific: does not need special recognition of the foreign cell. (2) Innate: does not need previous exposure.
More informationBIOTARGET-1 SERUM-FREE MEDIUM
TECHNICAL INFORMATION BIOTARGET-1 SERUM-FREE MEDIUM Cat. No. 05-080-1 Introduction The BIOTARGET-1 formulation has been developed specifically for use with mononuclear cells (lymphocytes and monocytes)
More informationNOTES: CH 43, part 2 Immunity; Immune Disruptions ( )
NOTES: CH 43, part 2 Immunity; Immune Disruptions (43.3-43.4) Activated B & T Lymphocytes produce: CELL-MEDIATED IMMUNE RESPONSE: involves specialized T cells destroying infected host cells HUMORAL IMMUNE
More informationKinetics of Primary and Memory Cytotoxic. T Lymphocyte Responses to Herpes. Simplex Virus 1 Infection: Granzyme B. Mediated CTL Activity
ISSN 1735-1383 Iran. J. Immunol. March 2009, 6 (1), 22-27 Masumeh Gorgian Mohammadi, Taravat Bamdad, Masoud Parsania, Hamid Reza Hashemi, Somayeh Puyanfard Kinetics of Primary and Memory Cytotoxic T Lymphocyte
More informationJyotika Sharma, Feng Dong, Mustak Pirbhai, and Guangming Zhong*
INFECTION AND IMMUNITY, July 2005, p. 4414 4419 Vol. 73, No. 7 0019-9567/05/$08.00 0 doi:10.1128/iai.73.7.4414 4419.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Inhibition
More informationimmunity produced by an encounter with an antigen; provides immunologic memory. active immunity clumping of (foreign) cells; induced by crosslinking
active immunity agglutination allografts immunity produced by an encounter with an antigen; provides immunologic memory. clumping of (foreign) cells; induced by crosslinking of antigenantibody complexes.
More informationDiagnostic Rates Vary Based Upon the Number of Read Days Using the
JCM Accepts, published online ahead of print on 4 September 2013 J. Clin. Microbiol. doi:10.1128/jcm.02006-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Diagnostic Rates
More informationHow is it transferred?
STI s What is a STI? It is a contagious infection that is transferred from one person to another through sexual intercourse or other sexually- related behaviors. How is it transferred? The organisms live
More informationxcelligence Real-Time Cell Analyzers
xcelligence Real-Time Cell Analyzers Application Note No. 9 A New Way to Monitor Virus-Mediated Cytopathogenicity Introduction One of the most important procedures in virology is the measurement of viral
More informationProduction of Interferon Alpha by Dengue Virus-infected Human Monocytes
J. gen. Virol. (1988), 69, 445-449. Printed in Great Britain 445 Key words: IFN-ct/dengue virus/monocytes Production of Interferon Alpha by Dengue Virus-infected Human Monocytes By ICHIRO KURANE AND FRANCIS
More informationHIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual)
HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual) BACKGROUND Human Immunodeficiency Virus ( HIV ) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to
More informationAGAINST VIRAL INFECTIONS. Identify the types of immunity involve in the mechanisms of protection against viral infections.
LECTURE: 02 Title: THE IMMUNOLOGICAL PROTECTIVE MECHANISMS AGAINST VIRAL INFECTIONS LEARNING OBJECTIVES: The student should be able to: Identify the types of immunity involve in the mechanisms of protection
More informationFoundations in Microbiology
Foundations in Microbiology Fifth Edition Talaro Chapter 15 The Acquisition of Specific Immunity and Its Applications Chapter 15 2 Chapter Overview 1. Development of the Dual Lymphocyte System 2. Entrance
More informationIMMUNOLOGY BIO 463 LABORATORY EXERCISE FALL 2015
IMMUNOLOGY BIO 463 LABORATORY EXERCISE FALL 2015 IL-2 Production in mouse splenocytes INTRODUCTION Interleukin-2, or IL-2, is a potent cytokine produced by T-cells, stimulating their proliferation. As
More informationPathogens and the immune system
Pathogens and the immune system Veronica Leautaud, Ph.D. vl2@ rice.edu Keck Hall 224 / 232-lab Lecture 8 BIOE 301-Bioengineering and World Health Review of lecture 7 Science Science is the human activity
More informationhuman Total Cathepsin B Catalog Number: DY2176
human Total Cathepsin B Catalog Number: DY2176 This DuoSet ELISA Development kit contains the basic components required for the development of sandwich ELISAs to measure natural and recombinant human Total
More informationThe Immune System: The Mind Body Connection. Presented by Margaret Kemeny, Ph.D. Department of Psychiatry, University of California, San Francisco
The Immune System: The Mind Body Connection Presented by Margaret Kemeny, Ph.D. Department of Psychiatry, University of California, San Francisco Psychoneuroimmunology Investigation of the bidirectional
More informationRadioimmunoassay of Herpes Simplex Virus Antibody: Correlation with Ganglionic Infection
J. gen. Virol. (I977), 3 6, ~ 371-375 Printed in Great Britain 371 Radioimmunoassay of Herpes Simplex Virus Antibody: Correlation with Ganglionic Infection By B. FORGHANI, TONI KLASSEN AND J. R. BARINGER
More informationJoseph E. Blaney, Jr.,* Jennifer M. Matro, Brian R. Murphy, and Stephen S. Whitehead
JOURNAL OF VIROLOGY, May 2005, p. 5516 5528 Vol. 79, No. 9 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.9.5516 5528.2005 Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a
More informationTesting for Herpes Simplex Infections Getting it DONE!
Testing for Herpes Simplex Infections Getting it DONE! Tens of millions of people have been diagnosed with herpes infections Genital Herpes Issues The Most Common Cause of Genital Ulceration is is Herpes
More informationAbstract: I. A ims Aim 1:
Abstract: Previous work from our laboratory demonstrated that obese mice have alterations in antiviral cytokine gene expression when infected with the influenza virus. Since these cytokines play a major
More informationIMMUNOGLOBULIN LEVELS IN SERUM AND CERVICOVAGINAL SECRETIONS OF PATIENTS INFECTED WITH TRICHOMONAS VAGINALIS
Journal of Al-Nahrain University Vol13 (2), June, 2010, pp147-151 Science IMMUNOGLOBULIN LEVELS IN SERUM AND CERVICOVAGINAL SECRETIONS OF PATIENTS INFECTED WITH TRICHOMONAS VAGINALIS Ekhlas Mushrif *,
More information17a. Sexually Transmitted Diseases and AIDS. BIOLOGY OF HUMANS Concepts, Applications, and Issues. Judith Goodenough Betty McGuire
BIOLOGY OF HUMANS Concepts, Applications, and Issues Fifth Edition Judith Goodenough Betty McGuire 17a Sexually Transmitted Diseases and AIDS Lecture Presentation Anne Gasc Hawaii Pacific University and
More informationSTD Epidemiology. Jonathan Zenilman, MD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationTopics in Parasitology BLY Vertebrate Immune System
Topics in Parasitology BLY 533-2008 Vertebrate Immune System V. Vertebrate Immune System A. Non-specific defenses against pathogens 1. Skin - physical barrier a. Tough armor protein KERATIN b. Surface
More informationDifference in Cytokine Production and Cell Activation between Adenoidal Lymphocytes and Peripheral Blood Lymphocytes of Children with Otitis Media
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Sept. 2005, p. 1130 1134 Vol. 12, No. 9 1071-412X/05/$08.00 0 doi:10.1128/cdli.12.9.1130 1134.2005 Copyright 2005, American Society for Microbiology. All
More informationHuman Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set
Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set Catalog Number : SEK11695 To achieve the best assay results, this manual must be read carefully before using this product
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationThe Lymphatic System and Immunity. Chapters 20 & 21
The Lymphatic System and Immunity Chapters 20 & 21 Objectives 1. SC.912.L.14.52 - Explain the basic functions of the human immune system, including specific and nonspecific immune response, vaccines, and
More informationCan We Use Biomarkers in Microbicide Trials to Predict Efficacy & Safety? Betsy C. Herold, MD Mount Sinai School of Medicine New York, NY
Can We Use Biomarkers in Microbicide Trials to Predict Efficacy & Safety? Betsy C. Herold, MD Mount Sinai School of Medicine New York, NY Attributes of Effective Microbicide Active against R5 and X4 isolates
More informationOncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More informationSIV p27 ANTIGEN CAPTURE ASSAY
SIV p27 ANTIGEN CAPTURE ASSAY Enzyme Immunoassay for the detection of Simian Immunodeficiency Virus (SIV) p27 in tissue culture media Catalog #5436 and #5450 Version 6; 12/2012 ABL PRODUCTS AND SERVICES
More informationWhat makes the transmitted HIV-1 in newly infected patients unique from the donor inoculum?
What makes the transmitted HIV-1 in newly infected patients unique from the donor inoculum? What happens during primary infection? Los Alamos National Laboratories Evidence of the genetic bottleneck at
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationThe Role of ST6 GAL-I sialyltransferase on immune responses to LCMV Infection
University of Tennessee, Knoxville Trace: Tennessee Research and Creative Exchange University of Tennessee Honors Thesis Projects University of Tennessee Honors Program 12-2008 The Role of ST6 GAL-I sialyltransferase
More informationMouse Anti-OVA IgM Antibody Assay Kit
Mouse Anti-OVA IgM Antibody Assay Kit Catalog # 3017 For Research Use Only - Not Human or Therapeutic Use INTRODUCTION Ovalbumin (OVA) is a widely used antigen for inducing allergic reactions in experimental
More informationMolecular and Cellular Basis of Immune Protection of Mucosal Surfaces
Molecular and Cellular Basis of Immune Protection of Mucosal Surfaces Department of Biologic & Materials Sciences School of Dentistry University of Michigan Ann Arbor, Michigan 48109-1078 1 Image quality
More informationHerpes Simplex Virus 1-2
Yamilet Melendez Microbiology 1 Presentation Herpes Simplex Virus 1-2 Introduction Herpes viruses are a leading cause of human viral diseases, second only to influenza and cold viruses Are capable of causing
More informationSupplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs
Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs (idcs) and mature DCs (mdcs). A myeloma cell line expressing
More informationReducing the Sexual Transmission of Genital Herpes
CLINICAL GUIDELINE Reducing the Sexual Transmission of Genital Herpes Compiled by Adrian Mindel Introduction People diagnosed with genital herpes usually have many questions and concerns, a key one being
More informationChapter 22: The Lymphatic System and Immunity
Bio40C schedule Lecture Immune system Lab Quiz 2 this week; bring a scantron! Study guide on my website (see lab assignments) Extra credit Critical thinking questions at end of chapters 5 pts/chapter Due
More informationSupplemental Information. Gut Microbiota Promotes Hematopoiesis to Control Bacterial Infection. Cell Host & Microbe, Volume 15
Cell Host & Microbe, Volume 15 Supplemental Information Gut Microbiota Promotes Hematopoiesis to Control Bacterial Infection Arya Khosravi, Alberto Yáñez, Jeremy G. Price, Andrew Chow, Miriam Merad, Helen
More informationnumber Done by Corrected by Doctor Sameer
number Immunology Done by Tamara and Hiba Corrected by Rana Ghassan Doctor Sameer Immunology In the development of cells, we have certain stages that take place: 1) Multi potential 1 hematopoietic stem
More informationViral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment
JOURNAL OF VIROLOGY, Apr. 2003, p. 4911 4927 Vol. 77, No. 8 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.8.4911 4927.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Viral Persistence
More informationLaboratory diagnosis of congenital infections
Laboratory diagnosis of congenital infections Laboratory diagnosis of HSV Direct staining Tzanck test Immunostaining HSV isolation Serology PCR Tzanck test Cell scrape from base of the lesion smear on
More informationThe Immune System is the Third Line of Defense Against Infection. Components of Human Immune System
Chapter 17: Specific Host Defenses: The Immune Response The Immune Response Immunity: Free from burden. Ability of an organism to recognize and defend itself against specific pathogens or antigens. Immune
More information